Insilico, Tenacia expand AI CNS pact in deal worth up to $94.75M
CURRENT FULL VERSION: Insilico Medicine and Tenacia Biotechnology have widened their AI-driven CNS drug discovery alliance, turning a one-program collaboration into a broader partnership with potential value of up to $94.75 million. In a March 26 announcement, the companies said they will add another program aimed at difficult neurological diseases, again emphasizing small molecules with defined properties and central nervous system relevance. The new agreement keeps Insilico in the discovery engine role and gives it access to near-term and milestone payments if the work advances. (prnewswire.com)
The expansion follows an initial collaboration announced on March 3, 2025, when the two companies said they would work on early discovery of novel CNS therapies using Insilico’s Pharma.AI platform and Tenacia’s neuroscience expertise. That first agreement centered on blood-brain barrier-penetrant small molecule inhibitors, a notable focus in CNS drug development because many otherwise promising compounds fail to reach therapeutic concentrations in the brain. Tenacia described itself at the time as a commercial-stage biopharmaceutical company focused on underserved neurological disorders, and said it was founded in 2022 by Bain Capital. (eurekalert.org)
In the latest expansion, the companies said the original program has been progressing smoothly over the past year, which appears to have set the stage for a second candidate effort against the same broad challenge area. According to the release, the partners now plan to jointly develop an additional innovative candidate and advance it to the preclinical candidate stage. Insilico said the aim is to explore molecules with distinct profiles for highly challenging nervous system conditions, with the broader goal of reducing late-stage development risk and improving the chance of differentiated clinical benefit. (prnewswire.com)
The deal also lands at a moment when Insilico is trying to show that its platform can generate both pipeline assets and business development momentum. In the 2025 Tenacia announcement, the company said it had built a wholly owned pipeline of 30 assets since 2021, with 10 IND clearances, and that CNS is one of its core focus areas. It also pointed to its blood-brain barrier-penetrant NLRP3 inhibitor program, ISM8969, as evidence that it can work on neurologic and neuroinflammatory targets. More broadly, Insilico has become part of a larger wave of AI-drug discovery dealmaking that accelerated in 2024 and has continued into 2026. Nature’s Biopharma Dealmakers described generative AI platforms as a growing force in biopharma partnering, especially for companies seeking faster small-molecule discovery. (eurekalert.org)
Industry reaction has mostly come through deal activity rather than outside expert critique so far. Just days after the Tenacia expansion, Insilico disclosed a separate global licensing and research collaboration with Eli Lilly worth up to $2.75 billion. Under that agreement, Lilly will gain exclusive global rights to develop, manufacture, and commercialize Insilico’s preclinical oral candidates for selected indications, and the companies will also work together on multiple Lilly-selected R&D programs using Pharma.AI across several therapeutic areas. Insilico is set to receive $115 million upfront, with additional development, regulatory, and commercial milestones plus tiered royalties on future sales. That much larger transaction suggests large pharma continues to validate AI-enabled discovery platforms, even as the sector still faces pressure to prove that computational speed translates into clinical and commercial wins. NVIDIA, one of Insilico’s technology partners, has also highlighted the company as an example of end-to-end generative AI drug discovery, pointing to claims of shorter timelines and lower preclinical costs than traditional approaches. (wtbx.com; PharmaShots)
Why it matters: For veterinary professionals, the direct commercial impact is limited today because this is a human biopharma CNS partnership, not an animal health program. But it’s still relevant as a readout on where discovery infrastructure is heading. Neurologic disease remains a difficult category across species, and the blood-brain barrier challenge is just as familiar in veterinary medicine as it is in human medicine. If AI-driven platforms become better at identifying druggable targets, designing brain-penetrant molecules, and triaging weak candidates earlier, those capabilities could eventually influence companion animal neurology, translational research, and licensing strategies in veterinary pharma. The bigger takeaway is that repeat collaborations matter: they suggest partners are seeing enough operational value in AI-assisted discovery to deepen commitments before human efficacy data are available. The Lilly deal strengthens that readout by showing that Insilico’s model is being used not only for single-program partnerships but also for broader licensing and multi-program research structures. (prnewswire.com; PharmaShots)
There’s also a cautionary note. AI drug discovery remains a fast-growing but still maturing segment, and the field’s boldest claims are ahead of long-term proof in many programs. Insilico has published and publicized progress on internally discovered assets, including a Phase II program in fibrosis, but the broader question for the industry is whether these tools consistently improve success rates, not just speed. For clinicians and veterinary industry watchers, that distinction matters: faster candidate generation is useful only if it leads to safer, more effective medicines. (eurekalert.org)
What to watch: The next markers will be whether Insilico and Tenacia disclose the biological target, when the new program reaches preclinical candidate nomination, and whether Insilico continues turning platform momentum into additional large partnerships after the Tenacia expansion and Lilly deal. For the Lilly collaboration itself, watch how many programs are activated, which therapeutic areas are prioritized, and whether any of Insilico’s preclinical oral candidates move forward under Lilly’s exclusive global rights. (prnewswire.com; PharmaShots)